Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13445910 | 0.98 | SMN1; SMN2 (0.33) | SMN1; SMN2KMT2AALOX12PSMB8PSMB5 | |
| SCHEMBL18073438 | 0.97 | KMT2A (0.31) | SMN1; SMN2KMT2AALOX12PSMB8PSMB5 | |
| SCHEMBL277769 | 0.95 | SMN1; SMN2 (0.32) | SMN1; SMN2KMT2AALOX12PSMB8PSMB5 | |
| SCHEMBL28711763 | 0.93 | ALOX12 (0.36) | SMN1; SMN2KMT2AALOX12PSMB8PSMB5 | |
| SCHEMBL24136289 | 0.92 | SMN1; SMN2 (0.41) | SMN1; SMN2KMT2APSMB8PSMB5HPGD | |
| SCHEMBL915308 | 0.92 | SMN1; SMN2 (0.41) | SMN1; SMN2KMT2APSMB8PSMB5HPGD | |
| SCHEMBL25962486 | 0.92 | SMN1; SMN2 (0.41) | SMN1; SMN2KMT2APSMB8PSMB5HPGD | |
| SCHEMBL5092849 | 0.92 | TSHR (0.33) | SMN1; SMN2KMT2AALOX12PSMB8PSMB5 | |
| SCHEMBL10314664 | 0.92 | GAA (0.33) | SMN1; SMN2KMT2AALOX12PSMB8PSMB5 | |
| SCHEMBL26186366 | 0.91 | SMN1; SMN2 (0.38) | SMN1; SMN2KMT2AALOX12PSMB8PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180117168-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | COLE RODERIC O (US) | 2018-05-03 | — | — | US | disclosed |
| US-20170369651-A1 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO | INSERT THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9550860-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550860-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160166567-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160101185-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160058873-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | CERULEAN PHARMA INC (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160058875-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8110179-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2012-01-05 | — | — | US | disclosed |
| US-20110245201-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110178287-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110160159-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110152512-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. | 2011-06-23 | — | — | US | disclosed |
| US-20080058427-A1 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7270808-B2 | Having covalently coupled bioactive agent and targeting ligand; controlled release; stability, solubility; reduced toxicity | INSERT THERAPEUTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | SMN1; SMN2 1075/4885KMT2A 4479/4885ALOX12 4776/4885 |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | SMN1; SMN2 1075/4885KMT2A 4479/4885ALOX12 4776/4885 |
| US-20160058873-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | IAPP, PRCP, DDOST | SMN1; SMN2 1666/4885KMT2A 4785/4885ALOX12 4769/4885 |
| US-20160101185-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | SMN1; SMN2 3422/4885KMT2A 1678/4885ALOX12 2835/4885 |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | SMN1; SMN2 1075/4885KMT2A 4479/4885ALOX12 4776/4885 |
| US-20080058427-A1 | Cyclodextrin-based polymers for therapeutics delivery | DDOST, DSC1, SI | SMN1; SMN2 1514/4885KMT2A 4639/4885ALOX12 4379/4885 |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | SMN1; SMN2 1201/4885KMT2A 3427/4885ALOX12 4743/4885 |
| US-20160166567-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | SMN1; SMN2 3422/4885KMT2A 1678/4885ALOX12 2835/4885 |
| US-20110160159-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | SMN1; SMN2 3422/4885KMT2A 1678/4885ALOX12 2835/4885 |
| US-20180117168-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | JAK2, JAK3, JAK1 | SMN1; SMN2 3526/4885KMT2A 2914/4885ALOX12 4774/4885 |
| US-20110245201-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | SMN1; SMN2 3422/4885KMT2A 1678/4885ALOX12 2835/4885 |
| US-20160058875-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | SMN1; SMN2 3422/4885KMT2A 1678/4885ALOX12 2835/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | SMN1; SMN2 422/4885KMT2A 4529/4885ALOX12 3900/4885 |
| US-20170369651-A1 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO | SDCBP, DDOST, CD47 | SMN1; SMN2 1957/4885KMT2A 4458/4885ALOX12 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.